Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Projected Market Size and Growth Rates for the Non-Cystic Fibrosis Bronchiectasis Market From 2025 To 2029?
The market size of non-cystic fibrosis bronchiectasis has seen robust growth in recent times. The market is projected to swell from $3.5 billion in 2024 to $3.74 billion in 2025, boasting a compound annual growth rate (CAGR) of 6.9%. The compelling growth witnessed in the past can be credited to factors like growing incidence and prevalence of the disease, advancements in diagnostic technologies, a rising elderly population, support and funding from the government, improved facilities in healthcare, heightened diagnosis awareness, an expanding geriatric population, and exposure to certain environmental factors.
What Is the Projected Market Size of the Non-Cystic Fibrosis Bronchiectasis Market?
Anticipated to witness robust expansion in the coming years, the market size of non-cystic fibrosis bronchiectasis is predicted to reach $4.82 billion in 2029, with a compound annual growth rate (CAGR) of 6.6%. The predicted growth within the forecast period can be accredited to advancements in individualized medicine, the introduction of new biomarkers, heightened investment in respiratory medicine, burgeoning research and development, public health campaigns, the worldwide aging demographic, and the evolution of specific therapy methods. Significant trends anticipated during the forecast period incorporate digital health remedies, a concentration on targeted treatments, the incorporation of AI and machine learning, a transition to home-based care, patient-oriented strategies, and the expansion of mobile health (mHealth) solutions.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17209&type=smp
Who are the Major Competitors in the Non-Cystic Fibrosis Bronchiectasis Market Outlook?
Major companies operating in the non-cystic fibrosis bronchiectasis market are Pfizer Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc (GSK), Boehringer Ingelheim International GmbH, Viatris Inc, Teva Pharmaceutical Industries Ltd, Vertex Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Dr Reddy’s Laboratories Ltd, Chiesi Farmaceutici SpA, Lupin Limited, Zambon Company SpA, Sunovion Pharmaceuticals Inc, Insmed Incorporated, Genentech, Zydus Cadila, Santhera Pharmaceuticals, TSRL Inc
What Is Fueling Growth in the Non-Cystic Fibrosis Bronchiectasis Market?
The non-cystic fibrosis bronchiectasis market is anticipated to experience growth due to the increasing incidence of respiratory diseases. Conditions impacting the lungs and respiratory system, and subsequently affecting breathing and overall respiratory functionality, fall under the umbrella of respiratory diseases. Mainly, environmental pollution, inclusive of outdoor contaminants and indoor annoyances like tobacco smoke, is driving the surge in respiratory diseases. There’s also a rising trend of respiratory infections, which potentially opens up opportunities for better understanding, diagnosing, and managing non-cystic fibrosis bronchiectasis via directed interventions and public health initiatives. For instance, data published by the Office for Health Improvement and Disparities, a UK governmental agency, in June 2023, indicates that between week 37 and week 46 of the 2022-2023 season, there were a total of 4,622 reported cases of Group A Streptococcus bacteria, a causal agent of scarlet fever, in England. A whopping 851 cases were reported in week 46 alone, a significant jump from the average 1,294 cases (ranging between 258 and 2,008) reported during the same timeframe (weeks 37 to 46) in the preceding five years. Therefore, the mounting incidence of respiratory diseases is likely to serve as a catalyst for the growth of the non-cystic fibrosis bronchiectasis market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=17209&type=smp
Which Non-Cystic Fibrosis Bronchiectasis Market Segments Are Growing the Fastest?
The non-cystic fibrosis bronchiectasis market covered in this report is segmented –
1) By Diagnosis: Computed Tomography (CT) Scan, Bronchoscopy, Chest X Ray, Lung Function, Sputum Culture Test, Blood Tests, Other Diagnosis Types
2) By Treatment: Surgery, Physiotherapy, Vaccination, Airway Pharmacotherapy, Antibiotics, Other Treatments
3) By End Use: Hospitals And Clinics, Ambulatory Care Centers, Other End Uses
Subsegments:
1) By Computed Tomography (CT) Scan: High-Resolution CT (HRCT), Standard CT
2) By Bronchoscopy: Flexible Bronchoscopy, Rigid Bronchoscopy
3) By Chest X-Ray: Standard Chest X-Ray, Digital Chest X-Ray
4) By Lung Function: Spirometry, Peak Flow Measurement
5) By Sputum Culture Test: Bacterial Culture, Fungal Culture, Viral Culture
6) By Blood Tests: Complete Blood Count (CBC), C-Reactive Protein (CRP), Immunoglobulin Levels
7) By Other Diagnosis Types: Sweat Test, Genetic Testing, Exhaled Nitric Oxide Test
Which Industry Trends Are Shaping the Future of the Non-Cystic Fibrosis Bronchiectasis Market?
Leading firms in the non-cystic fibrosis bronchiectasis industry are adopting personalized medicine strategies such as nebulization solutions to improve the efficiency of medication delivery and increase patient compliance. Nebulization solutions provide state-of-the-art technology for the accurate and effective administration of respiratory drugs, which enhances patient adherence and the success of treatments. For instance, Zambon S.P.A, a multinational pharmaceutical corporation based in Italy, achieved a US FDA designation for CMS I-neb therapy for patients with non-cystic fibrosis bronchiectasis (NCFB) in April 2022. CMS I-neb is an under-investigation treatment, anticipated to be the first-of-its-kind inhaled therapy for adult patients with NCFB colonized with P. aeruginosa. NCFB is a chronic, progressive, and incurable respiratory ailment. The breakthrough designation affirms the registration route for CMS I-neb in NCFB and potentially fast-tracks its development and assessment.
Access The Full Report Here:
Which Countries Are Leading the Non-Cystic Fibrosis Bronchiectasis Market?
North America was the largest region in the non-cystic fibrosis bronchiectasis market in 2023. The regions covered in the non-cystic fibrosis bronchiectasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17209
This Report Delivers Insight On:
1. How big is the non-cystic fibrosis bronchiectasis market, and how is it changing globally?
2. Who are the major companies in the non-cystic fibrosis bronchiectasis market, and how are they performing?
3. What are the key opportunities and risks in the non-cystic fibrosis bronchiectasis market right now?
4. Which products or customer segments are growing the most in the non-cystic fibrosis bronchiectasis market?
5. What factors are helping or slowing down the growth of the non-cystic fibrosis bronchiectasis market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
